Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-GemOx in Relapsed/Refractory Aggressive Lymphomas
NCT01562977Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Apr 2011
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, gemcitabine, oxaliplatin, dexamethasone in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), sponsored by GELTAMO. Started Apr 2011; status: completed.
02
Drugs
rituximabgemcitabineoxaliplatindexamethasone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01562977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562977.